OS THERAPIES INC

Os Therapies (OTX) trades below its 200‑day SMA yet within a tight 52‑week band— a stable, value‑oriented biopharma play focused on osteosarcoma with a robust Phase II/III pipeline and emerging partnership prospects.

OS Therapies shares dip 3.8% after a $1.32 closing, yet its new inducement offer fuels a capital boost for osteosarcoma drug development.